Skip to main content
Top
Published in: Neurological Sciences 9/2017

01-09-2017 | Original Article

Osteopontin and clusterin levels in type 2 diabetes mellitus: differential association with peripheral autonomic nerve function

Authors: Raelene E. Maser, M. James Lenhard, Ryan T. Pohlig, P. Babu Balagopal

Published in: Neurological Sciences | Issue 9/2017

Login to get access

Abstract

Osteopontin (OPN) and clusterin are secreted glycoproteins potentially associated with nerve function. Sudomotor dysfunction is associated with the development of foot ulcerations. The purpose of this study was to investigate the potential relationship of OPN and clusterin with sudomotor function (i.e., autonomic nerves that control sweating) in participants with type 2 diabetes mellitus (T2DM). Sudomotor function was assessed using SUDOSCAN® which measures electrochemical skin conductance (ESC) of the hands and feet. Demographics (e.g., age, gender, race, body mass index (BMI)), HbA1c, 25-hydroxyvitamin D, creatinine, OPN, and clusterin were also determined for the participants. Fifty individuals with T2DM (age = 59±11 years; 23/27 male/female; 13 African Americans) participated in this study. Lower ESC for the hands and feet were observed in African Americans versus Caucasians/Asians (p < 0.05). No significant ESC differences were observed for good [HbA1c <7%] versus poor [HbA1c ≥7%] glycemic control. With regard to gender, ESC values were lower for the hands for females (p < 0.05). In linear regression with ESC for the hands or feet as the dependent variable, increased OPN levels, but not clusterin, were independently associated with reduced sudomotor function while adjusting for age, gender, race, BMI, and glycemic control (ESC hands model R 2 = 0.504, p < 0.001; ESC feet model R 2 = 0.534, p < 0.001). The association between OPN and reduced sudomotor function found in our study warrants further investigation to delineate the underlying mechanisms and determine if OPN is neuroprotective, involved in the pathogenesis of sudomotor dysfunction, or simply a bystander.
Literature
1.
go back to reference Wright MC, Mi R, Connor E, Reed N, Vyas A, Alspalter M, Coppola G, Geschwind DH, Brushart TM, Hoke A (2014) Novel roles for osteopontin and clusterin in peripheral motor and sensory axon regeneration. J Neurosci 34:1689–1700CrossRefPubMedPubMedCentral Wright MC, Mi R, Connor E, Reed N, Vyas A, Alspalter M, Coppola G, Geschwind DH, Brushart TM, Hoke A (2014) Novel roles for osteopontin and clusterin in peripheral motor and sensory axon regeneration. J Neurosci 34:1689–1700CrossRefPubMedPubMedCentral
2.
go back to reference Kazanecki CC, Uzwiak DJ, Denhardt DT (2007) Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem 102:912–924CrossRefPubMed Kazanecki CC, Uzwiak DJ, Denhardt DT (2007) Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem 102:912–924CrossRefPubMed
3.
go back to reference Jander S, Bussini S, Neuen-Jacob E, Bosse F, Menge T, Muller HW, Stoll G (2002) Osteopontin: a novel axon-regulated Schwann cell gene. J Neurosci Res 67:156–166CrossRefPubMed Jander S, Bussini S, Neuen-Jacob E, Bosse F, Menge T, Muller HW, Stoll G (2002) Osteopontin: a novel axon-regulated Schwann cell gene. J Neurosci Res 67:156–166CrossRefPubMed
4.
go back to reference Park S, Mathis KW, Lee IK (2014) The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases. Rev Endocr Metab Disord 15:45–53CrossRefPubMed Park S, Mathis KW, Lee IK (2014) The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases. Rev Endocr Metab Disord 15:45–53CrossRefPubMed
5.
go back to reference Schrijvers EM, Koudstaal PJ, Hofman A, Breteler MM (2011) Plasma clusterin and the risk of Alzheimer disease. JAMA 305:1322–1326CrossRefPubMed Schrijvers EM, Koudstaal PJ, Hofman A, Breteler MM (2011) Plasma clusterin and the risk of Alzheimer disease. JAMA 305:1322–1326CrossRefPubMed
6.
go back to reference Nuutinen T, Suuronen T, Kauppinen A, Salminen A (2009) Clusterin: a forgotten player in Alzheimer's disease. Brain Res Rev 61:89–104CrossRefPubMed Nuutinen T, Suuronen T, Kauppinen A, Salminen A (2009) Clusterin: a forgotten player in Alzheimer's disease. Brain Res Rev 61:89–104CrossRefPubMed
7.
go back to reference Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, Sosenko JM, Ziegler D (2017) Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 40:136–154CrossRefPubMed Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, Sosenko JM, Ziegler D (2017) Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 40:136–154CrossRefPubMed
8.
go back to reference Vinik AI, Nevoret ML, Casellini C (2015) The new age of sudomotor function testing: a sensitive and specific biomarker for diagnosis, estimation of severity, monitoring progression, and regression in response to intervention. Front Endocrinol 6:94CrossRef Vinik AI, Nevoret ML, Casellini C (2015) The new age of sudomotor function testing: a sensitive and specific biomarker for diagnosis, estimation of severity, monitoring progression, and regression in response to intervention. Front Endocrinol 6:94CrossRef
9.
go back to reference Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P, Toronto Diabetic Neuropathy Expert Group (2010) Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 33:2285–2293CrossRefPubMedPubMedCentral Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P, Toronto Diabetic Neuropathy Expert Group (2010) Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 33:2285–2293CrossRefPubMedPubMedCentral
10.
go back to reference Chahal S, Vohra K, Syngle A (2017) Association of sudomotor function with peripheral artery disease in type 2 diabetes. Neurol Sci 38:151–156CrossRefPubMed Chahal S, Vohra K, Syngle A (2017) Association of sudomotor function with peripheral artery disease in type 2 diabetes. Neurol Sci 38:151–156CrossRefPubMed
11.
go back to reference Tentolouris N, Marinou K, Kokotis P, Karanti A, Diakoumopoulou E, Katsilambros N (2009) Sudomotor dysfunction is associated with foot ulceration in diabetes. Diabet Med 26:302–305CrossRefPubMed Tentolouris N, Marinou K, Kokotis P, Karanti A, Diakoumopoulou E, Katsilambros N (2009) Sudomotor dysfunction is associated with foot ulceration in diabetes. Diabet Med 26:302–305CrossRefPubMed
13.
go back to reference Boulton AJ (2004) The diabetic foot: from art to science. The 18th Camillo Golgi lecture. Diabetologia 47:1343–1353CrossRefPubMed Boulton AJ (2004) The diabetic foot: from art to science. The 18th Camillo Golgi lecture. Diabetologia 47:1343–1353CrossRefPubMed
14.
go back to reference Vinik AI, Casellini C, Nevoret ML (2016) Alternative quantitative tools in the assessment of diabetic peripheral and autonomic neuropathy. Int Rev Neurobiol 127:235–285CrossRefPubMed Vinik AI, Casellini C, Nevoret ML (2016) Alternative quantitative tools in the assessment of diabetic peripheral and autonomic neuropathy. Int Rev Neurobiol 127:235–285CrossRefPubMed
16.
go back to reference Singh R, Kishore L, Kaur N (2014) Diabetic peripheral neuropathy: current perspective and future directions. Pharmacol Res 80:21–35CrossRefPubMed Singh R, Kishore L, Kaur N (2014) Diabetic peripheral neuropathy: current perspective and future directions. Pharmacol Res 80:21–35CrossRefPubMed
17.
18.
go back to reference Sytze Van Dam P, Cotter MA, Bravenboer B, Cameron NE (2013) Pathogenesis of diabetic neuropathy: focus on neurovascular mechanisms. Eur J Pharmacol 719:180–186CrossRefPubMed Sytze Van Dam P, Cotter MA, Bravenboer B, Cameron NE (2013) Pathogenesis of diabetic neuropathy: focus on neurovascular mechanisms. Eur J Pharmacol 719:180–186CrossRefPubMed
19.
go back to reference Maser RE, Lenhard MJ, Pohlig RT, Balagopal PB (2016) Osteopontin and osteoprotegerin levels in type 2 diabetes and their association with cardiovascular autonomic function. J Diabetes Complicat 30:507–510CrossRefPubMed Maser RE, Lenhard MJ, Pohlig RT, Balagopal PB (2016) Osteopontin and osteoprotegerin levels in type 2 diabetes and their association with cardiovascular autonomic function. J Diabetes Complicat 30:507–510CrossRefPubMed
20.
go back to reference Morisaki Y, Niikura M, Watanabe M, Onishi K, Tanabe S, Moriwaki Y, Okuda T, Ohara S, Murayama S, Takao M, Uchida S, Yamanaka K, Misawa H (2016) Selective expression of osteopontin in ALS-resistant motor neurons is a critical determinant of late phase neurodegeneration mediated by matrix metalloproteinase-9. Sci Rep 6:27354CrossRefPubMedPubMedCentral Morisaki Y, Niikura M, Watanabe M, Onishi K, Tanabe S, Moriwaki Y, Okuda T, Ohara S, Murayama S, Takao M, Uchida S, Yamanaka K, Misawa H (2016) Selective expression of osteopontin in ALS-resistant motor neurons is a critical determinant of late phase neurodegeneration mediated by matrix metalloproteinase-9. Sci Rep 6:27354CrossRefPubMedPubMedCentral
22.
go back to reference Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J (2002) Osteopontin—a molecule for all seasons. QJM 95:3–13CrossRefPubMed Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J (2002) Osteopontin—a molecule for all seasons. QJM 95:3–13CrossRefPubMed
24.
go back to reference Magalhaes J, Saraiva MJ (2011) Clusterin overexpression and its possible protective role in transthyretin deposition in familial amyloidotic polyneuropathy. J Neuropathol Exp Neurol 70:1097–1106CrossRefPubMed Magalhaes J, Saraiva MJ (2011) Clusterin overexpression and its possible protective role in transthyretin deposition in familial amyloidotic polyneuropathy. J Neuropathol Exp Neurol 70:1097–1106CrossRefPubMed
25.
go back to reference Wilson MR, Easterbrook-Smith SB (2000) Clusterin is a secreted mammalian chaperone. Trends Biochem Sci 25:95–98CrossRefPubMed Wilson MR, Easterbrook-Smith SB (2000) Clusterin is a secreted mammalian chaperone. Trends Biochem Sci 25:95–98CrossRefPubMed
26.
go back to reference Trougakos IP (2013) The molecular chaperone apolipoprotein J/clusterin as a sensor of oxidative stress: implications in therapeutic approaches—a mini-review. Gerontology 59:514–523CrossRefPubMed Trougakos IP (2013) The molecular chaperone apolipoprotein J/clusterin as a sensor of oxidative stress: implications in therapeutic approaches—a mini-review. Gerontology 59:514–523CrossRefPubMed
27.
go back to reference Vinik AI, Smith AG, Singleton JR, Callaghan B, Freedman BI, Tuomilehto J, Bordier L, Bauduceau B, Roche F (2016) Normative values for electrochemical skin conductances and impact of ethnicity on quantitative assessment of sudomotor function. Diabetes Technol Ther 18:391–398CrossRefPubMed Vinik AI, Smith AG, Singleton JR, Callaghan B, Freedman BI, Tuomilehto J, Bordier L, Bauduceau B, Roche F (2016) Normative values for electrochemical skin conductances and impact of ethnicity on quantitative assessment of sudomotor function. Diabetes Technol Ther 18:391–398CrossRefPubMed
28.
go back to reference Smith AG, Lessard M, Reyna S, Doudova M, Singleton JR (2014) The diagnostic utility of Sudoscan for distal symmetric peripheral neuropathy. J Diabetes Complicat 28:511–516CrossRefPubMedPubMedCentral Smith AG, Lessard M, Reyna S, Doudova M, Singleton JR (2014) The diagnostic utility of Sudoscan for distal symmetric peripheral neuropathy. J Diabetes Complicat 28:511–516CrossRefPubMedPubMedCentral
29.
go back to reference Parson HK, Nguyen VT, Orciga MA, Boyd AL, Casellini CM, Vinik AI (2013) Contact heat-evoked potential stimulation for the evaluation of small nerve fiber function. Diabetes Technol Ther 15:150–157CrossRefPubMed Parson HK, Nguyen VT, Orciga MA, Boyd AL, Casellini CM, Vinik AI (2013) Contact heat-evoked potential stimulation for the evaluation of small nerve fiber function. Diabetes Technol Ther 15:150–157CrossRefPubMed
30.
go back to reference Gibbons CH, Illigens BM, Wang N, Freeman R (2009) Quantification of sweat gland innervation: a clinical-pathologic correlation. Neurology 72:1479–1486CrossRefPubMedPubMedCentral Gibbons CH, Illigens BM, Wang N, Freeman R (2009) Quantification of sweat gland innervation: a clinical-pathologic correlation. Neurology 72:1479–1486CrossRefPubMedPubMedCentral
31.
go back to reference Ang L, Jaiswal M, Martin C, Pop-Busui R (2014) Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep 14:528CrossRefPubMedPubMedCentral Ang L, Jaiswal M, Martin C, Pop-Busui R (2014) Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep 14:528CrossRefPubMedPubMedCentral
32.
go back to reference Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393CrossRefPubMed Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393CrossRefPubMed
Metadata
Title
Osteopontin and clusterin levels in type 2 diabetes mellitus: differential association with peripheral autonomic nerve function
Authors
Raelene E. Maser
M. James Lenhard
Ryan T. Pohlig
P. Babu Balagopal
Publication date
01-09-2017
Publisher
Springer Milan
Published in
Neurological Sciences / Issue 9/2017
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-017-3019-1

Other articles of this Issue 9/2017

Neurological Sciences 9/2017 Go to the issue